Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions (mainly private M&A/private equity and venture capital) with a focus on telecommunication, energy and life sciences. In addition, he advises mainly medium-sized and start-up companies and SMEs on questions of corporate governance, compliance, restructuring and all other legal aspects of day-to-day business operations. Robert von Rosen is a board member of several corporations and foundations (e.g. Optiswiss Ltd, Holle baby food Ltd. GRS Wieland Foundation).

After completing an apprenticeship in banking, Robert von Rosen studied at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). During that time, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law. Before joining Walder Wyss, Robert von Rosen worked for eight years at a leading Swiss law firm, supplemented by a secondment with the Swiss Financial Market Supervisory Authority FINMA.

Robert von Rosen practices in German and English. He is registered with the Basel bar registry and is also admitted to the bar in Germany.

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

CONVOTIS stärkt seine Position in der Schweiz durch die neueste Akquisition der acdalis AG, einem anerkannten Spezialisten für Managed Cloud und Infrastruktur Services.

Coopers acquires iET Group

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

The Best Lawyers Awards 2024

GEODIS acquires ITS - International Transport & Shipping Ltd. and expands its freight forwarding offering in Switzerland

Datacolor acquires matchmycolor

PwC Switzerland acquires Avoras

Skribble AG completes Series A round of funding

groupe.id joins Elvaston

Elvaston sells Magnolia International AG to GENUI

Cawood acquires IES Ltd

proLogistik Holding GmbH acquiert XELOG AG

Dr. Wild & Co. AG cède son activité pharmacie à Verfora SA

Boehringer Ingelheim rachète NBE-Therapeutics pour 1,18 milliard d’euros

Financement de série A de CHF 54 millions de Noema Pharma

Synendos Therapeutics CHF 20m Series A Financing

Tour de table série B de 19 millions CHF de BioVersys

Versant Ventures lance Matterhorn Biosciences

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg rachète Bilcare Research Group

GrandVision reprend McOptic

Boehringer Ingelheim acquiert Amal Therapeutics

CHF 12.5 Million financing round in Alentis Therapeutics AG

NNIT A/S übernimmt Halfmann Goetsch Partner AG

Precision Surfacing Solutions achète le commerce de découpe de plaques (wafers) de Meyer Burger

SHS investit dans l’entreprise suisse de Sciences de la vie evitria SA

Cellestia Biotech SA: tour de financement de série A de CHF 20 mio

BC Platforms CHF 10 mio., tour de table d'investissement série B

RWS acquires LUZ, Inc.

Reprise de SkyVision par Spadina House AG

Cession par Acino de son activité de pansements transdermiques à Luye Pharma Group Ltd.

Bayer et CRISPR Therapeutics créent une coentreprise d’édition génomique

Honeywell fait l’acquisition d’Aviaso

Achat et refinancement de Boost Holding AG

Energiedienst Holding AG et TRITEC rassemblent leur savoir-faire

Avanade acquiert KCS.net

P&I Personal & Informatik AG rachète la branche RH de Soreco SA

SVC-SA pour le capital-risque des PME prend une participation minoritaire dans Stratpharma AG

Valens Clinics acquire Rheinburg Clinics

Reconnaissances